Publications

1. Chen VP, Gao Y, Geng L, Brimijoin S. Butyrylcholinesterase regulates central ghrelin signaling and has an impact on food intake and glucose homeostasis. Int J Obes (Lond). 2017 Sep; 41 (9):1413-1419 Epub 2017 May 22
   View PubMed
2. Gao Y, Geng L, Chen VP, Brimijoin S. Therapeutic Delivery of Butyrylcholinesterase by Brain-Wide Viral Gene Transfer to Mice. Molecules. 2017 Jul 8; 22 (7) Epub 2017 July 08
   View PubMed
3. Peng H, Blake TA, Johnson RC, Dafferner AJ, Brimijoin S, Lockridge O. Monoclonal antibodies that recognize various folding states of pure human butyrylcholinesterase can immunopurify butyrylcholinesterase from human plasma stored at elevated temperatures ACS Omega. 2016 Dec; 1: (6)1182-91.
   
4. Brimijoin S, Chen VP, Pang YP, Geng L, Gao Y. Physiological roles for butyrylcholinesterase: A BChE-ghrelin axis. Chem Biol Interact. 2016 Nov 25; 259 (Pt B):271-275 Epub 2016 Feb 23
   View PubMed
5. Chen VP, Gao Y, Geng L, Stout MB, Jensen MD, Brimijoin S. Butyrylcholinesterase Deficiency Promotes Adipose Tissue Growth and Hepatic Lipid Accumulation in Male Mice on High-Fat Diet. Endocrinology. 2016 Aug; 157 (8):3086-95 Epub 2016 June 14
   View PubMed
6. Smethells JR, Swalve N, Brimijoin S, Gao Y, Parks RJ, Greer A, Carroll ME. Long-Term Blockade of Cocaine Self-Administration and Locomotor Activation in Rats by an Adenoviral Vector-Delivered Cocaine Hydrolase. J Pharmacol Exp Ther. 2016 May; 357: (2)375-81.
   View PubMed
7. Murthy V, Reyes S, Geng L, Gao Y, Brimijoin S. Cocaine Hydrolase Gene Transfer Demonstrates Cardiac Safety and Efficacy against Cocaine-Induced QT Prolongation in Mice. J Pharmacol Exp Ther. 2016 Mar; 356: (3)720-5.
   View PubMed
8. Peng H, Brimijoin S, Hrabovska A, Krejci E, Blake TA, Johnson RC, Masson P, Lockridge O. Monoclonal antibodies to human butyrylcholinesterase reactive with butyrylcholinesterase in animal plasma. Chem Biol Interact. 2016 Jan 5; 243:82-90 Epub 2015 Nov 14
   View PubMed
9. Chen VP, Gao Y, Geng L, Brimijoin S. Radiometric assay of ghrelin hydrolase activity and 3H-ghrelin distribution into mouse tissues. Biochem Pharmacol. 2015 Dec 15; 98: (4)732-9.
   View PubMed
10. Pope C, Uchea C, Flynn N, Poindexter K, Geng L, Brimijoin WS, Hartson S, Ranjan A, Ramsey JD, Liu J. In vitro characterization of cationic copolymer-complexed recombinant human butyrylcholinesterase. Biochem Pharmacol. 2015 Dec 1; 98 (3):531-9 Epub 2015 Oct 08
    View PubMed
11. Peng H, Brimijoin S, Hrabovska A, Targosova K, Krejci E, Blake TA, Johnson RC, Masson P, Lockridge O. Comparison of 5 monoclonal antibodies for immunopurification of human butyrylcholinesterase on Dynabeads: KD values, binding pairs, and amino acid sequences. Chem Biol Interact. 2015 Oct 5; 240:336-45 Epub 2015 Sept 03
    View PubMed
12. Murthy V, Geng L, Gao Y, Zhang B, Miller JD, Reyes S, Brimijoin S. Reward and Toxicity of Cocaine Metabolites Generated by Cocaine Hydrolase. Cell Mol Neurobiol. 2015 Aug; 35 (6):819-26 Epub 2015 Mar 27
    View PubMed
13. Chen X, Huang X, Geng L, Xue L, Hou S, Zheng X, Brimijoin S, Zheng F, Zhan CG. Kinetic characterization of a cocaine hydrolase engineered from mouse butyrylcholinesterase. Biochem J. 2015 Mar 1; 466 (2):243-51
    View PubMed
14. Chen VP, Gao Y, Geng L, Parks RJ, Pang YP, Brimijoin S. Plasma butyrylcholinesterase regulates ghrelin to control aggression. Proc Natl Acad Sci U S A. 2015 Feb 17; 112 (7):2251-6 Epub 2015 Feb 02
    View PubMed
15. Murthy V, Gao Y, Geng L, LeBrasseur NK, White TA, Parks RJ, Brimijoin S. Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice. Vaccine. 2014 Jul 16; 32 (33):4155-62 Epub 2014 June 02
    View PubMed
16. Murthy V, Gao Y, Geng L, LeBrasseur N, White T, Brimijoin S. Preclinical studies on neurobehavioral and neuromuscular effects of cocaine hydrolase gene therapy in mice. J Mol Neurosci. 2014 Jul; 53 (3):409-16 Epub 2013 Oct 02
    View PubMed
17. Zlebnik NE, Brimijoin S, Gao Y, Saykao AT, Parks RJ, Carroll ME. Long-term reduction of cocaine self-administration in rats treated with adenoviral vector-delivered cocaine hydrolase: evidence for enzymatic activity. Neuropsychopharmacology. 2014 May; 39: (6)1538-46.
    View PubMed
18. Flynn N, Uchea C, Pope J, Hartson S, Vupputuri S, Geng L, Brimijoin S, Ranjan A, Pope C, Ramsey JD. Encapsulation of butyrylcholinesterase with a cationic copolymer library Food, Pharmaceutical and Bioengineering Division 2014 - Core Programming Area at the 2014 AIChE Annual Meeting. 2014; 1:124-5.
    
19. Larrimore KE, Barcus M, Kannan L, Gao Y, Zhan CG, Brimijoin S, Mor T. Plants as a source of butyrylcholinesterase variants designed for enhanced cocaine hydrolase activity. Chem Biol Interact. 2013 Mar 25; 203(1):217-20. Epub 2012 Sep 20.
    View PubMed
20. Brimijoin S, Shen X, Orson F, Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines. 2013 Mar; 12: (3)323-32.
    View PubMed
21. Gao J, Li Y, Zhu N, Brimijoin S, Sui N. Roles of dopaminergic innervation of nucleus accumbens shell and dorsolateral caudate-putamen in cue-induced morphine seeking after prolonged abstinence and the underlying D1- and D2-like receptor mechanisms in rats. J Psychopharmacol. 2013 Feb; 27(2):181-91. Epub 2012 Nov 13.
    View PubMed
22. Geng L, Gao Y, Chen X, Hou S, Zhan CG, Radic Z, Parks RJ, Russell SJ, Pham L, Brimijoin S. Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity. PLoS One. 2013; 8 (6):e67446 Epub 2013 June 28
    View PubMed
23. Anker JJ, Brimijoin S, Gao Y, Geng L, Zlebnik NE, Parks RJ, Carroll ME. Cocaine hydrolase encoded in viral vector blocks the reinstatement of cocaine seeking in rats for 6 months. Biol Psychiatry. 2012 Apr 15; 71(8):700-5. Epub 2011 Dec 30.
    View PubMed
24. Seo S, Lomberk G, Mathison A, Buttar N, Podratz J, Calvo E, Iovanna J, Brimijoin S, Windebank A, Urrutia R. Kruppel-like factor 11 differentially couples to histone acetyltransferase and histone methyltransferase chromatin remodeling pathways to transcriptionally regulate dopamine D2 receptor in neuronal cells. J Biol Chem. 2012 Apr 13; 287: (16)12723-35.
    View PubMed
25. Pang YP, Brimijoin S, Ragsdale DW, Zhu KY, Suranyi R. Novel and viable acetylcholinesterase target site for developing effective and environmentally safe insecticides. Curr Drug Targets. 2012 Apr; 13 (4):471-82
    View PubMed
26. Brimijoin S, Gao Y. Cocaine hydrolase gene therapy for cocaine abuse. Future Med Chem. 2012 Feb; 4: (2)151-62.
    View PubMed
27. Brimijoin S. Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users. CNS Neurol Disord Drug Targets. 2011 Dec; 10: (8)880-91.
    View PubMed
28. Carroll ME, Gao Y, Brimijoin S, Anker JJ. Effects of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats. Psychopharmacology (Berl). 2011 Feb; 213(4):817-29.
    
29. Polsinelli GA, Singh SK, Mishra RK, Suranyi R, Ragsdale DW, Pang YP, Brimijoin S. Insect-specific irreversible inhibitors of acetylcholinesterase in pests including the bed bug, the eastern yellowjacket, German and American cockroaches, and the confused flour beetle. Chem Biol Interact. 2010 Sep 6; 187 (1-3):142-7 Epub 2010 Jan 28
    View PubMed
30. Gao Y, Orson FM, Kinsey B, Kosten T, Brimijoin S. The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem Biol Interact. 2010 Sep 6; 187: (1-3)421-4.
    View PubMed
31. Pang YP, Ekstrom F, Polsinelli GA, Gao Y, Rana S, Hua DH, Andersson B, Andersson PO, Peng L, Singh SK, Mishra RK, Zhu KY, Fallon AM, Ragsdale DW, Brimijoin S. Selective and irreversible inhibitors of mosquito acetylcholinesterases for controlling malaria and other mosquito-borne diseases. PLoS One. 2009 Aug 28; 4 (8):e6851
    View PubMed
32. Gao Y, Brimijoin S. Lasting reduction of cocaine action in neostriatum--a hydrolase gene therapy approach. J Pharmacol Exp Ther. 2009 Aug; 330 (2):449-57 Epub 2009 May 28
    View PubMed
33. Ray A, Liu J, Karanth S, Gao Y, Brimijoin S, Pope C. Cholinesterase inhibition and acetylcholine accumulation following intracerebral administration of paraoxon in rats. Toxicol Appl Pharmacol. 2009 May 1; 236(3):341-7. Epub 2009 Mar 06.
    View PubMed
34. Tang H, Pavel J, Saavedra JM, Brimijoin S. Type-1 angiotensin receptors are expressed and transported in motor and sensory axons of rat sciatic nerves. Neuropeptides. 2009 Apr; 43: (2)81-92.
    View PubMed
35. Pang YP, Singh SK, Gao Y, Lassiter TL, Mishra RK, Zhu KY, Brimijoin S. Selective and irreversible inhibitors of aphid acetylcholinesterases: steps toward human-safe insecticides. PLoS One. 2009; 4(2):e4349. Epub 2009 Feb 04.
    View PubMed
36. Hu W, Gray NW, Brimijoin S. Amyloid-beta alters trafficking of internalized acetylcholinesterase and dextran. International Journal of Physiology, Pathophysiology and Pharmacology. 2009; 1(1):15-24.
    View PubMed
37. Pavel J, Tang H, Brimijoin S, Moughamian A, Nishioku T, Benicky J, Saavedra JM. Expression and transport of Angiotensin II AT1 receptors in spinal cord, dorsal root ganglia and sciatic nerve of the rat. Brain Res. 2008 Dec 30; 1246:111-22. Epub 2008 Oct 17.
    View PubMed
38. Brimijoin S, Gao Y, Anker JJ, Gliddon LA, Lafleur D, Shah R, Zhao Q, Singh M, Carroll ME. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology. 2008 Oct; 33 (11):2715-25 Epub 2008 Jan 16
    View PubMed
39. Gao Y, LaFleur D, Shah R, Zhao Q, Singh M, Brimijoin S. An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact. 2008 Sep 25; 175 (1-3):83-7 Epub 2008 May 01
    View PubMed
40. Tang H, Pavel J, Saavedra JM, Brimijoin S. Angiotensin II type 1 receptors may not influence response of spinal autonomic neurons to axonal damage. Neurol Res. 2008 Sep; 30 (7):751-60 Epub 2008 May 21
    View PubMed
41. Lassiter TL, Brimijoin S. Rats gain excess weight after developmental exposure to the organophosphorothionate pesticide, chlorpyrifos. Neurotoxicol Teratol. 2008 Mar-Apr; 30(2):125-30. Epub 2007 Nov 06.
    View PubMed
42. Brimijoin S. Neuroscience in China. Cell Mol Neurobiol. 2008 Jan; 28(1):1-2. Epub 2007 Nov 14.
    View PubMed
43. Garcia-Ayllon MS, Silveyra MX, Andreasen N, Brimijoin S, Blennow K, Saez-Valero J. Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease. J Neurochem. 2007 Jun; 101(6):1701-11. Epub 2007 Feb 26.
    View PubMed
44. Lassiter TL, Brimijoin S. A method to determine precise benchmark doses for carbamate anticholinesterases. Toxicol Sci. 2007 Mar; 96(1):154-61. Epub 2006 Dec 11.
    View PubMed
45. Darreh-Shori T, Brimijoin S, Kadir A, Almkvist O, Nordberg A. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol Dis. 2006 Nov; 24(2):326-33. Epub 2006 Sep 14.
    View PubMed
46. Gao Y, Brimijoin S. Viral transduction of cocaine hydrolase in brain reward centers. Cell Mol Neurobiol. 2006 Jul-Aug; 26 (4-6):357-63 Epub 2006 May 18
    View PubMed
47. Gao Y, Brimijoin S. Visualizing viral transduction of a cocaine-hydrolyzing, human butyrylcholinesterase in rats. Chem Biol Interact. 2005 Dec 15; 157-158:97-103 Epub 2005 Oct 21
    View PubMed
48. Rees TM, Berson A, Sklan EH, Younkin L, Younkin S, Brimijoin S, Soreq H. Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. Curr Alzheimer Res. 2005 Jul; 2(3):291-300.
    View PubMed
49. Brimijoin S. Can cholinesterase inhibitors affect neural development? Environ Toxicol Pharmacol. 2005 May; 19(3):429-32. Epub 2005 Feb 12.
    View PubMed
50. Gao Y, Atanasova E, Sui N, Pancook JD, Watkins JD, Brimijoin S. Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. Mol Pharmacol. 2005 Jan; 67 (1):204-11 Epub 2004 Oct 01
    View PubMed
51. Gao Y, Brimijoin S. An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J Pharmacol Exp Ther. 2004 Sep; 310(3):1046-52. Epub 2004 Apr 20.
    View PubMed
52. Conti AM, Brimijoin S, Miller LJ, Windebank AJ. Suppression of neurite outgrowth by high-dose nerve growth factor is independent of functional p75NTR receptors. Neurobiol Dis. 2004 Feb; 15(1):106-14.
    View PubMed
53. Rees T, Hammond PI, Soreq H, Younkin S, Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging. 2003 Oct; 24(6):777-87.
    View PubMed
54. Hammond PI, Kern C, Hong F, Kollmeyer TM, Pang YP, Brimijoin S. Cholinesterase reactivation in vivo with a novel bis-oxime optimized by computer-aided design. J Pharmacol Exp Ther. 2003 Oct; 307 (1):190-6 Epub 2003 July 31
    View PubMed
55. Hu W, Gray NW, Brimijoin S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J Neurochem. 2003 Jul; 86(2):470-8.
    View PubMed
56. Pang YP, Kollmeyer TM, Hong F, Lee JC, Hammond PI, Haugabouk SP, Brimijoin S. Rational design of alkylene-linked bis-pyridiniumalidoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun; 10(6):491-502.
    View PubMed
57. Leelakusolvong S, Bharucha AE, Sarr MG, Hammond PI, Brimijoin S, Phillips SF. Effect of extrinsic denervation on muscarinic neurotransmission in the canine ileocolonic region. Neurogastroenterol Motil. 2003 Apr; 15(2):173-86.
    View PubMed
58. Hammond PI, Craig TA, Kumar R, Brimijoin S. Regional and cellular distribution of DREAM in adult rat brain consistent with multiple sensory processing roles. Brain Res Mol Brain Res. 2003 Mar 17; 111: (1-2)104-10.
    View PubMed
59. Rees TM, Brimijoin S. The role of acetylicholinesterase in the pathogenesis of Alzheimer's disease. Drugs of Today. 2003 Jan; 39(1):75-83.
    View PubMed
60. Zhang H, Brimijoin S, Tang X-C. Apoptosis by β-amyloid25-35 in acetylcholine-esterase-overexpressing neuroblastoma cells. Acta Pharmacol Sinica. 2003; 24:853-858.
    
61. Brimijoin S, Shen ML, Sun H. Radiometric solvent-partitioning assay for screening cocaine hydrolases and measuring cocaine levels in milligram tissue samples. Anal Biochem. 2002 Oct 15; 309 (2):200-5
    View PubMed
62. Tang H, Brimijoin S. Death of preganglionic sympathetic neurons after surgical or immunologic lesion of peripheral processes. Exp Neurol. 2002 Sep; 177(1):105-14.
    View PubMed
63. Sun H, Pang YP, Lockridge O, Brimijoin S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol. 2002 Aug; 62 (2):220-4
    View PubMed
64. Sun H, Shen ML, Pang YP, Lockridge O, Brimijoin S. Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J Pharmacol Exp Ther. 2002 Aug; 302 (2):710-6
    View PubMed
65. Tang H, Brimijoin S. Complement regulatory proteins and selective vulnerability of neurons to lysis on exposure to acetylcholinesterase antibody. J Neuroimmunol. 2001 Apr 2; 115 (1-2):53-63
    View PubMed
66. Sun H, El Yazal J, Lockridge O, Schopfer LM, Brimijoin S, Pang YP. Predicted Michaelis-Menten complexes of cocaine-butyrylcholinesterase. Engineering effective butyrylcholinesterase mutants for cocaine detoxication. J Biol Chem. 2001 Mar 23; 276 (12):9330-6 Epub 2000 Dec 04
    View PubMed
67. Sharma KV, Brimijoin S, Koenigsberger C, Bigbee J. Acetylcholinesterase modulates the adhesion of neuroblastoma cells. J Neurosci Res ,. 2001; 63: 165-75.
    
68. Li B, Stribley JA, Ticu A, Xie W, Schopfer LM, Hammond P, Brimijoin S, Hinrichs S, Lockridge O. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J. Neurochem.. 2001; 75: 1320-31.
    
69. Atanasova E, Chiappa S, Wieben E, Brimijoin S. Novel messenger RNA and alternative promoter for murine acetylcholinesterase. J Biol Chem. 1999 Jul 23; 274(30):21078-84.
    View PubMed
70. Tang H, Miller SM, Ermilov LG, Lennon VA, Brimijoin S. Complement-mediated lesion of sympathetic ganglia in vitro with acetylcholinesterase antibodies. J Neuroimmunol. 1999 Jun 1; 97 (1-2):86-93
    View PubMed
71. Brimijoin S, Koenigsberger C. Cholinesterases in neural development: new findings and toxicologic implications. Environ Health Perspect. 1999 Feb; 107 Suppl 1:59-64
    View PubMed
72. Veenstra TD, Prufer K, Koenigsberger C, Brimijoin SW, Grande JP, Kumar R. 1,25-Dihydroxyvitamin D3 receptors in the central nervous system of the rat embryo. Brain Res. 1998 Sep 7; 804: (2)193-205.
    View PubMed
73. Pang YP, Brimijoin S. Supercomputing-based dimeric analog approach for drug optimization. Parallel Comput. 1998 Sep; 24(9-10):1557-1566.
    
74. Tang H, Hammond P, Brimijoin S. Acetylcholinesterase immunolesioning: regional vulnerability of preganglionic sympathetic neurons in rat spinal cord. Exp Neurol. 1998 Aug; 152(2):167-76.
    View PubMed
75. Koenigsberger C, Hammond P, Brimijoin S. Developmental expression of acetyl- and butyrylcholinesterase in the rat: enzyme and mRNA levels in embryonic dorsal root ganglia. Brain Res. 1998 Mar 23; 787 (2):248-58
    View PubMed
76. Mortensen SR, Brimijoin S, Hooper MJ, Padilla S. Comparison of the in vitro sensitivity of rat acetylcholinesterase to chlorpyrifos-oxon: what do tissue IC50 values represent? Toxicol Appl Pharmacol. 1998 Jan; 148(1):46-9.
    View PubMed
77. Miller SM, Ermilov LG, Szurszewski JH, Hammond PI, Brimijoin S. Selective disruption of neurotransmission by acetylcholinesterase antibodies in sympathetic ganglia examined with intracellular microelectrodes. J Auton Nerv Syst. 1997 Dec 11; 67(3):156-67.
    View PubMed
78. Koenigsberger C, Chiappa S, Brimijoin S. Neurite differentiation is modulated in neuroblastoma cells engineered for altered acetylcholinesterase expression. J Neurochem. 1997 Oct; 69(4):1389-97.
    View PubMed
79. Veenstra TD, Londowski JM, Windebank AJ, Brimijoin S, Kumar R. Effects of 1,25-dihydroxyvitamin D3 on growth of mouse neuroblastoma cells. Brain Res Dev Brain Res. 1997 Mar 17; 99: (1)53-60.
    View PubMed
80. Pang YP, Hong F, Quiram P, Jelacic T, Brimijoin S. Synthesis of alkylene linked bis-THA and alkylene linked benzyl-THA as highly potent and selective inhibitors and molecular probes of acetylcholinesterase. J Chem Soc Perkin Trans. 1997 Jan 21(2):171-6.
    
81. Holgert H, Holmberg K, Hannibal J, Fahrenkrug J, Brimijoin S, Hartman BK, Hokfelt T. PACAP in the adrenal gland--relationship with choline acetyltransferase, enkephalin and chromaffin cells and effects of immunological sympathectomy. Neuroreport. 1996 Dec 20; 8(1):297-301.
    View PubMed
82. Holgert H, Lagercrantz H, Dagerlind A, Hartman BK, Cozzari C, Brimijoin S, Hokfelt T. Effects of immunological sympathectomy on postnatal peptide expression in the rat adrenal medulla. Brain Res Dev Brain Res. 1996 Nov 22; 97(1):88-95.
    View PubMed
83. Hammond PI, Jelacic T, Padilla S, Brimijoin S. Quantitative, video-based histochemistry to measure regional effects of anticholinesterase pesticides in rat brain. Anal Biochem. 1996 Oct 1; 241(1):82-92.
    View PubMed
84. Pang YP, Quiram P, Jelacic T, Hong F, Brimijoin S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J Biol Chem. 1996 Sep 27; 271 (39):23646-9
    View PubMed
85. Wilson BW, Padilla S, Henderson JD, Brimijoin S, Dass PD, Elliot G, Jaeger B, Lanz D, Pearson R, Spies R. Factors in standardizing automated cholinesterase assays. J Toxicol Environ Health. 1996 Jun 7; 48(2):187-95.
    View PubMed
86. McKinzie S, Tyce GM, Brimijoin S. Lowered norepinephrine turnover as a sign of impaired ganglionic transmission after preganglionic lesioning by acetylcholinesterase antibodies. J Pharmacol Exp Ther. 1996 May; 277(2):817-22.
    View PubMed
87. Carmichael SW, Brimijoin WS. Looking at slow axonal transport. Microscopy Today. 1996; 96(9):3.
    
88. Brimijoin S, Hammond P. Transient expression of acetylcholinesterase mRNA and enzyme activity in developing rat thalamus studied by quantitative histochemistry and in situ hybridization. Neurosci. 1996; 71:555-565.
    
89. Holgert H, Åman K, Cozzari C, Hartman BK, Brimijoin S, Emson P, Goldstein M, Hökfelt T. The cholinergic innervation of the adrenal gland and its relation to enkephalin and nitric oxide synthase. Neuroreport. 1995 Dec 15; 6(18):2576-80.
    View PubMed
90. Brimijoin WS. Using antibodies to unwire the sympathetic nervous system. News Physiol Sci. 1995 Jun; 10:101-106.
    
91. Bruss M, Hammermann R, Brimijoin S, Bonisch H. Antipeptide antibodies confirm the topology of the human norepinephrine transporter. J Biol Chem. 1995 Apr 21; 270(16):9197-201.
    View PubMed
92. Russell JW, Windebank AJ, McNiven MA, Brat DJ, Brimijoin WS. Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity. Brain Res. 1995 Apr 10; 676(2):258-67.
    View PubMed
93. Li W, Ochalski PA, Brimijoin S, Jordan LM, Nagy JI. C-terminals on motoneurons: electron microscope localization of cholinergic markers in adult rats and antibody-induced depletion in neonates. Neuroscience. 1995 Apr; 65(3):879-91.
    View PubMed
94. Chiappa S, Padilla S, Koenigsberger C, Moser V, Brimijoin S. Slow accumulation of acetylcholinesterase in rat brain during enzyme inhibition by repeated dosing with chlorpyrifos. Biochem Pharmacol. 1995 Mar 30; 49(7):955-63.
    View PubMed
95. Brimijoin S, Dagerlind A, Rao R, McKinzie S, Hammond P. Accumulation of enkephalin, proenkephalin mRNA, and neuropeptide Y in immunologically denervated rat adrenal glands: evidence for divergent peptide regulation. J Neurochem. 1995 Mar; 64(3):1281-7.
    View PubMed
96. Rao R, Brimijoin S. Reverse transcriptase-polymerase chain reaction assay for acetylcholinesterase mRNA in rat brain. Neurochem Res. 1995 Feb; 20 (2):129-35
    View PubMed
97. Hammond P, Rao R, Koenigsberger C, Brimijoin S. Regional variation in expression of acetylcholinesterase mRNA in adult rat brain analyzed by in situ hybridization. Proc Natl Acad Sci U S A. 1994 Nov 8; 91: (23)10933-7.
    View PubMed
98. Mesulam MM, Brimijoin S, Geula C. Neurofibrillary tangles have no obligatory predilection for acetylcholinesterase-rich neurons. Neurobiol Aging. 1994 Sep-Oct; 15(5):615-9.
    View PubMed
99. Dagerlind A, Pelto-Huikko M, Lundberg JM, Ubink R, Verhofstad A, Brimijoin S, Hokfelt T. Immunologically induced sympathectomy of preganglionic nerves by antibodies against acetylcholinesterase: increased levels of peptides and their messenger RNAs in rat adrenal chromaffin cells. Neuroscience. 1994 Sep; 62(1):217-39.
    View PubMed
100. Brimijoin S, Hammond P, Khraibi AA, Tyce GM. Catecholamine release and excretion in rats with immunologically induced preganglionic sympathectomy. J Neurochem. 1994 Jun; 62(6):2195-204.
     View PubMed
101. Dagerlind A, Zhang X, Brimijoin S, Lindh B, Hokfelt T. Effects of preganglionic sympathectomy on peptides in the rat superior cervical ganglion. Neuroreport. 1994 Apr 14; 5(8):909-12.
     View PubMed
102. Brat DJ, Brimijoin S. Acrylamide and glycidamide impair neurite outgrowth in differentiating N1E.115 neuroblastoma without disturbing rapid bidirectional transport of organelles observed by video microscopy. J Neurochem. 1993 Jun; 60: (6)2145-52.
     View PubMed
103. Oka N, Brimijoin S. Altered spectrum of retrogradely transported axonal proteins in P-bromophylacetylurea neuropathy. Neurochem Res. 1993 Jun; 18:675-680.
     View PubMed
104. Dagerlind A, Brimijoin S, Goldstein M, Hokfelt T. Effects of antibodies against acetylcholinesterase on the expression of peptides and catecholamine synthesizing enzymes in the rat adrenal gland. Neuroscience. 1993 Jun; 54:1079-1090.
     View PubMed
105. Brimijoin S, Moser V, Hammond P, Oka N, Lennon VA. Death of intermediolateral spinal cord neurons follows selective, complement-mediated destruction of peripheral preganglionic sympathetic terminals by acetylcholinesterase antibodies. Neuroscience. 1993 May; 54(1):201-23.
     View PubMed
106. Rakonczay Z, Hammond P, Brimijoin S. Lesion of central cholinergic systems by systemically administered acetylcholinesterase antibodies in newborn rats. Neuroscience. 1993 May; 54(1):225-38.
     View PubMed
107. Brat DJ, Brimijoin S. A paradigm for examining toxicant effects on viability, structure, and axonal transport of neurons in culture. Mol Neurobiol. 1992 Summer-Fall; 6(2-3):125-35.
     View PubMed
108. Brat DJ, Windebank AJ, Brimijoin S. Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther. 1992 May; 261(2):803-10.
     View PubMed
109. Oka N, Brimijoin WS. Tubulomembranous lesions in p-bromophenylacetylurea neuropathy reflect local stasis of fast axonal transport: evidence from electron microscopic autoradiography. Mayo Clin Proc. 1992 Apr; 67 (4):341-8
     View PubMed
110. Padilla S, Moser VC, Pope CN, Brimijoin WS. Paraoxon toxicity is not potentiated by prior reduction in blood acetylcholinesterase. Toxicol Appl Pharmacol. 1992; 117:110-115.
     View PubMed
111. Bean AJ, Xu Z, Chai SY, Brimijoin S, Hokfelt T. Effect of intracerebral injection of monoclonal acetylcholinesterase antibodies on cholinergic nerve terminals in the rat central nervous system. Neurosci Lett. 1991 Nov 25; 133(1):145-9.
     View PubMed
112. Mesulam MM, Geula C, Cosgrove R, Mash D, Brimijoin S. Immunocytochemical demonstration of axonal and perikaryl in human cerebral cortex. Brain Res. 1991 Jan 25; 539:233-238.
     View PubMed
113. Brimijoin S, Lennon VA. Selective destruction of preganglionic sympathetic nerves by antibodies to acetylcholinesterase. J Neural Transm Suppl. 1991; 34:139-45.
     View PubMed
114. Brimijoin S, Lennon VA. Autoimmune preganglionic sympathectomy induced by acetylcholinesterase antibodies. Proc Natl Acad Sci U S A. 1990 Dec; 87: (24)9630-4.
     View PubMed
115. Oka N, Brimijoin S. Premature onset of fast axonal transport in bromophenylacetylurea neuropathy: an electrophoretic analysis of proteins exported into motor nerve. Brain Res. 1990 Feb 12; 509(1):107-10.
     View PubMed
116. Brimijoin S, Balm M, Hammond P, Lennon VA. Selective complexing of acetylcholinesterase in brain by intravenously administered monoclonal antibody. J Neurochem. 1990 Jan; 54(1):236-41.
     View PubMed
117. Studelska DR, Brimijoin S. Partial isolation of two classes of dopamine beta-hydroxylase-containing particles undergoing rapid axonal transport in rat sciatic nerve. J Neurochem. 1989 Aug; 53(2):622-31.
     View PubMed
118. Brimijoin S, Hammond P. Butyrylcholinesterase in human brain and acetylcholinesterase in human plasma: trace enzymes measured by two-site immunoassay. J Neurochem. 1988 Oct; 51 (4):1227-31
     View PubMed
119. Hammond P, Brimijoin S. Acetylcholinesterase in Huntington's and Alzheimer's diseases: simultaneous enzyme assay and immunoassay of multiple brain regions. J Neurochem. 1988 Apr; 50(4):1111-6.
     View PubMed
120. Nelson DK, Service JE, Studelska DR, Brimijoin S, Go VL. Gastrointestinal neuropeptide concentrations following guanethidine sympathectomy. J Auton Nerv Syst. 1988 Apr; 22 (3):203-10
     View PubMed
121. Nagata H, Brimijoin S, Low P, Schmelzer JD. Slow axonal transport in experimental hypoxia and in neuropathy induced by p-bromophenylacetylurea. Brain Res. 1987 Oct 06; 422: (2)319-26.
     View PubMed
122. Brimijoin S, Hammond P, Rakonczay Z. Two-site immunoassay for acetylcholinesterase in brain, nerve, and muscle. J Neurochem. 1987 Aug; 49(2):555-62.
     View PubMed
123. Brimijoin S, Rakonczay ZR, Hammond P. Immunoassay of acetylcholinesterase. Fed Proc. 1987 Jun; 46(8):2557-62.
     View PubMed
124. Pfeiffer GL, Brimijoin WS, Studelska DR, Carmichael SW. Electron microscopy of isolated mitochondrion-chromaffin vesicle complexes. Z Mikrosk Anat Forsch. 1987; 101(4):567-76.
     View PubMed
125. Brimijoin S, Rakonczay Z, Mintz K. Immunochemistry of mammalian cholinesterases. Fed Proc. 1986 Dec; 45(13):2960-4.
     View PubMed
126. Nagata H, Brimijoin S. Neurotoxicity of halogenated phenylacetylureas is linked to abnormal onset of rapid axonal transport. Brain Res. 1986 Oct 15; 385(1):136-42.
     View PubMed
127. Nagata H, Brimijoin S. Axonal transport in the motor neurons of rats with neuropathy induced by p-bromophenylacetylurea. Ann Neurol. 1986 May; 19(5):458-64.
     View PubMed
128. Rakonczay Z, Brimijoin S. Monoclonal antibodies to rat brain acetylcholinesterase: comparative affinity for soluble and membrane-associated enzyme and for enzyme from different vertebrate species. J Neurochem. 1986 Jan; 46(1):280-7.
     View PubMed
129. Brimijoin S, Rakonczay Z. Immunology and molecular biology of the cholinesterases: current results and prospects. Int Rev Neurobiol. 1986; 28:363-410.
     View PubMed
130. Brimijoin S, Hammond P, Petitt R. Paroxysmal nocturnal hemoglobinuria: Red cell acetylcholinesterase deficit analyzed by immunoassay and fluorescence-activated sorting. Mayo Clinic Proc. 1986; 61:522-529.
     
131. Brimijoin S, Mintz KP, Prendergast FG. An inhibitory monoclonal antibody to rabbit brain acetylcholinesterase. Studies on interaction with the enzyme. Mol Pharmacol. 1985 Dec; 28(6):539-45.
     View PubMed
132. Rakonczay Z, Brimijoin S. Immunochemical differences among molecular forms of acetylcholinesterase in brain and blood. Biochim Biophys Acta. 1985 Nov 29; 832(2):127-34.
     View PubMed
133. Mintz KP, Brimijoin S. Monoclonal antibodies to rabbit brain acetylcholinesterase: selective enzyme inhibition, differential affinity for enzyme forms, and cross- reactivity with other mammalian cholinesterases. J Neurochem. 1985 Jul; 45(1):284-92.
     View PubMed
134. Brimijoin S, Mintz KP. Human acetylcholinesterase. Immunochemical studies with monoclonal antibodies. Biochim Biophys Acta. 1985 Apr 29; 828(3):290-7.
     View PubMed
135. Low PA, Ward K, Schmelzer JD, Brimijoin S. Ischemic conduction failure and energy metabolism in experimental diabetic neuropathy. Am J Physiol. 1985 Apr; 248(4 Pt 1):E457-62.
     View PubMed
136. Studelska DR, Campbell NR, Brimijoin WS. Catecholamine binding by adrenal medullary protein can interfere with a sensitive radioenzymatic assay for norepinephrine. Life Sci. 1985 Mar 4; 36(9):881-7.
     View PubMed
137. Brimijoin WS, Hammond PI. Acrylamide neuropathy in the rat: effects on energy metabolism in sciatic nerve. Mayo Clin Proc. 1985 Jan; 60(1):3-8.
     View PubMed
138. Mintz KP, Brimijoin S. Two-step immunoaffinity purification of acetylcholinesterase from rabbit brain. J Neurochem. 1985 Jan; 44(1):225-32.
     View PubMed
139. Rakonczay Z, Brimijoin S. Monoclonal antibodies to human brain acetylcholinesterase: properties and applications. Cell Mol Neurobiol. 1985; 8:85-93.
     
140. Brimijoin S, Mintz KP. Unimpaired energy metabolism in experimental neuropathy induced by P-bromophenylacetylurea. Muscle Nerve. 1984 Nov/Dec; 7:725-732.
     View PubMed
141. Mintz KP, Weinshilboum RM, Brimijoin WS. Evolution of butyrylcholinesterase in higher primates: an immunochemical study. Comp Biochem Physiol C. 1984; 79(1):35-7.
     View PubMed
142. Brimijoin S, Mintz KP, Alley MC. Production and characterization of separate monoclonal antibodies to human acetylcholinesterase and butyrylcholinesterase. Mol Pharmacol. 1983 Nov; 24(3):513-20.
     View PubMed
143. Litchy WJ, Brimijoin S. Concentration dependence of rapid axonal transport: a study of the transport kinetics of [35S]methionine-labeled protein in postganglionic sympathetic fibers of the bullfrog. J Neurosci. 1983 Oct; 3(10):2075-82.
     View PubMed
144. Dyck PJ, Mellinger JF, Reagan TJ, Horowitz SJ, McDonald JW, Litchy WJ, Daube JR, Fealey RD, Go VLW, Kao PC, Brimijoin WS, Lambert EH. Not 'indifference to pain', but varieties of hereditary, sensory, and autonomic neuropathy. Brain. 1983 Jun; 106(PART II):373-390.
     View PubMed
145. Edwards JA, Brimijoin S. Effects of hypophysectomy on acetylcholinesterase and butyrylcholinesterase in the rat. Biochem Pharmacol. 1983 Apr 1; 32(7):1183-9.
     View PubMed
146. Brimijoin S, Mintz KP, Prendergast FG. Dansylarginine N-(3-ethyl-1.5-pentanediyl)amide. A potent and selective fluorescent inhibitor of butyrylcholinesterase. Biochem Pharmacol. 1983 Feb 15; 32(4):699-706.
     View PubMed
147. Edwards JA, Brimijoin S. Thermal inactivation of the molecular forms of acetylcholinesterase and butyrylcholinesterase. Biochim Biophys Acta. 1983 Feb 15; 742(3):509-16.
     View PubMed
148. Jakobsen J, Brimijoin S, Sidenius P. Axonal transport in neuropathy. Muscle Nerve. 1983 Feb; 6(2):164-6.
     View PubMed
149. Brimijoin S. Molecular forms of acetylcholinesterase in brain, nerve and muscle: nature, localization and dynamics. Prog Neurobiol. 1983; 21(4):291-322.
     View PubMed
150. Brimijoin WS. Abnormalities of axonal transport: are they a cause of peripheral nerve disease? Mayo Clin Proc. 1982 Nov; 57(11):707-14.
     View PubMed
151. Edwards JA, Brimijoin S. Divergent regulation of acetylcholinesterase and butyrylcholinesterase in tissues of the rat. J Neurochem. 1982 May; 38(5):1393-403.
     View PubMed
152. Brimijoin S, Schreiber PA. Reduced axonal transport of 10S acetylcholinesterase in dystrophic mice. Muscle Nerve. 1982 May-Jun; 5(5):405-10.
     View PubMed
153. Brimijoin S. Microtubules and the capacity of the system for rapid axonal transport. Fed Proc. 1982 May; 41(7):2312-6.
     View PubMed
154. Brimijoin S, Carter J. Turnover of the molecular forms of acetylcholinesterase in the rat diaphragm. J Neurochem. 1982 Feb; 38(2):588-90.
     View PubMed
155. Carter J, Lennon VA, Schreiber P, Brimijoin S. Content and release of acetylcholinesterase in skeletal muscle of rats with experimental autoimmune myasthenia gravis. Exp Neurol. 1982 Feb; 75(2):490-500.
     View PubMed
156. Jakobsen J, Lambert EH, Carlson G, Brimijoin S. Clinical and electrophysiological characteristics of the experimental neuropathy caused by p-bromophenylacetylurea. Exp Neurol. 1982 Jan; 75(1):158-72.
     View PubMed
157. Brimijoin S, Carlson G, Nguyen NN, Jakobsen J. Analogs of p-bromophenylacetylurea: a structure activity study of their neurotoxicity in rats. Muscle Nerve. 1982; 5(9S):S122-6.
     View PubMed
158. Jakobsen J, Brimijoin S. Axonal transport of enzymes and labeled proteins in experimental axonopathy induced by p-bromophenylacetylurea. Brain Res. 1981 Dec 14; 229(1):103-22.
     View PubMed
159. Skau KA, Brimijoin S. Abnormal distribution of skeletal muscle acetylcholinesterase molecular forms in dystrophic mice. Exp Neurol. 1981 Oct; 74(1):111-21.
     View PubMed
160. Jakobsen J, Brimijoin S, Skau K, Sidenius P, Wells D. Retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in streptozotocin-diabetic rats. Diabetes. 1981 Oct; 30(10):797-803.
     View PubMed
161. Lundberg JM, Fahrenkrug J, Brimijoin S. Characteristics of the axonal transport of vasoactive intestinal polypeptide (VIP) in nerves of the cat. Acta Physiol Scand. 1981 Aug; 112(4):427-36.
     View PubMed
162. Cater JL, Brimijoin S. Effects of acute and chronic denervation on release of acetylcholinesterase and its molecular forms in rat diaphragms. J Neurochem. 1981 Mar; 36(3):1018-25.
     View PubMed
163. Skau KA, Brimijoin S. Multiple molecular forms of acetylcholinesterase in rat vagus nerve, smooth muscle, and heart. J Neurochem. 1980 Nov; 35(5):1151-4.
     View PubMed
164. Evans BA, Yao JK, Holman RT, Brimijoin WS, Lambert EH, Dyck PJ. Structural and biochemical effects of essential fatty acid deficiency on peripheral nerve. J Neuropathol Exp Neurol. 1980 Nov; 39(6):683-91.
     View PubMed
165. Brimijoin S, Lundberg JM, Brodin E, Hokfelt T, Nilsson G. Axonal transport of substance P in the vagus and sciatic nerves of the guinea pig. Brain Res. 1980 Jun 9; 191(2):443-57.
     View PubMed
166. Lundberg JM, Hokfelt T, Anggard A, Uvnas-Wallensten K, Brimijoin S, Brodin E, Fahrenkrug J. Peripheral peptide neurons: distribution, axonal transport, and some aspects on possible function. Adv Biochem Psychopharmacol. 1980; 22:25-36.
     View PubMed
167. Brimijoin S, Dyck PJ. Axonal transport of dopamine-beta-hydroxylase and acetylcholinesterase in human peripheral neuropathy. Exp Neurol. 1979 Dec; 66(3):467-78.
     View PubMed
168. Dyck PJ, Carney JA, Sizemore GW, Okazaki H, Brimijoin WS, Lambert EH. Multiple endocrine neoplasia, type 2b: phenotype recognition; neurological features and their pathological basis. Ann Neurol. 1979 Oct; 6(4):302-14.
     View PubMed
169. Brimijoin S. On the kinetics and maximal capacity of the system for rapid axonal transport in mammalian neurones. J Physiol (Lond). 1979 Jul; 292: 325-37.
     View PubMed
170. Brimijoin S. Axonal transport and subcellular distribution of molecular forms of acetylcholinesterase in rabbit sciatic nerve. Mol Pharmacol. 1979 May; 15(3):641-8.
     View PubMed
171. Brimijoin S, Olsen J, Rosenson R. Comparison of the temperature-dependence of rapid axonal transport and microtubules in nerves of the rabbit and bullfrog. J Physiol (Lond). 1979 Feb; 287: 303-14.
     View PubMed
172. Starkey RR, Brimijoin S. Stop-flow analysis of the axonal transport of dopa decarboxylase (EC 4.1.1.26) in rabbit sciatic nerves. J Neurochem. 1979 Feb; 32(2):437-41.
     View PubMed
173. Brimijoin S, Wiermaa MJ. Rapid orthograde and retrograde axonal transport of acetylcholinesterase as characterized by the stop-flow technique. J Physiol (Lond). 1978 Dec; 285: 129-42.
     View PubMed
174. Brimijoin S, Skau K, Wiermaa MJ. On the origin and fate of external acetylcholinesterase in peripheral nerve. J Physiol (Lond). 1978 Dec; 285: 143-58.
     View PubMed
175. Skau KA, Brimijoin S. Release of acetylcholinesterase from rat hemidiaphragm preparations stimulated through the phrenic nerve. Nature. 1978 Sep 21; 275(5677):224-6.
     View PubMed
176. Brimijoin S. A histofluorescence study of events accompanying accumulation and migration of norepinephrine within locally cooled nerves. J Neurobiol. 1977 May; 8(3):251-63.
     View PubMed
177. Brimijoin S, Wiermaa MJ. Direct comparison of the rapid axonal transport of norepinephrine and dopamine-beta-hydroxylase activity. J Neurobiol. 1977 May; 8(3):239-50.
     View PubMed
178. Brimijoin S, Wiermaa MJ. Rapid axonal transport of tyrosine hydroxylase in rabbit sciatic nerves. Brain Res. 1977 Jan 31; 121(1):77-96.
     View PubMed
179. Ohnishi A, Schilling K, Brimijoin WS, Lambert EH, Fairbanks VF, Dyck PJ. Lead neuropathy: 1. Morphometry, nerve conduction, and choline acetyltransferase transport: new finding of endoneurial edema associated with segmental demyelination. J Neuropathol Exp Neurol. 1977; 36:499-518.
     View PubMed
180. Cosens B, Thacker D, Brimijoin S. Temperature-dependence of rapid axonal transport in sympathetic nerves of the rabbit. J Neurobiol. 1976 Jul; 7(4):339-54.
     View PubMed
181. Brimijoin S, Helland L. Rapid retrograde transport of dopamine-beta-hydroxylase as examined by the stop-flow technique. Brain Res. 1976 Feb 6; 102(2):217-28.
     View PubMed
182. Brimijoin S. Cycloheximide alters axonal transport and subcellular distribution of dopamine-beta-hydroxylase activity. J Neurochem. 1976 Jan; 26(1):35-40.
     View PubMed
183. Brimijoin S, Jablecki C. Reduced axonal transport of dopamine-beta-hydroxylase in dystrophic mice: evidence for abnormality of adrenergic nerve cells. Exp Neurol. 1976; 53:454-464.
     View PubMed
184. Jablecki C, Brimijoin S. Axoplasmic transport of choline acetyltransferase activity in mice: effect of age and neurotomy. J Neurochem. 1975 Nov; 25(5):583-93.
     View PubMed
185. Brimijoin S. Stop-flow: a new technique for measuring axonal transport, and its application to the transport of dopamine-beta-hydroxylase. J Neurobiol. 1975 Jul; 6(4):379-94.
     View PubMed
186. Jablecki C, Brimijoin S. Reduced axoplasmic transport of choline acetyltransferase activity in dystrophic mice. Nature. 1974 Jul 12; 250(462):151-4.
     View PubMed
187. Brimijoin S. Local changes in subcellular distribution of dopamine-beta-hydroxylase (EC 1.14.2.1) after blockade of axonal transport. J Neurochem. 1974 Mar; 22(3):347-53.
     View PubMed
188. Brimijoin WS. Evidence that 6-hydroxydopamine decreases synthesis of dopamine-beta-hydroxylase in sympathetic ganglia. J Pharmacol Exp Ther. 1972 Nov; 183:298-306.
     View PubMed
189. Brimijoin WS. Transport and turnover of dopamine-beta-hydroxylase (EC 1.14.2.1) in sympathetic nerves of the rat. J Neurochem. 1972 Sep; 19:2183-93.
     View PubMed
190. Molinoff PB, Brimijoin WS, Axelrod J. Induction of dopamine-beta-hydroxylase and tyrosine hydroxylase in rat hearts and sympathetic ganglia. J Pharmacol Exp Ther. 1972 Jul; 182:116-29.
     View PubMed
191. Silberstein SD, Lemberger L, Brimijoin WS, Molinoff PB. Induction of dopamine-beta-hydroxylase in rat superior cervical ganglia in organ culture. J Neurochem. 1972 Mar; 19:919-21.
     View PubMed
192. Brimijoin S, Molinoff PB. Effects of 6-hydroxydopamine on the activity of tyrosine hydroxylase and dopamine- -hydroxylase in sympathetic ganglia of the rat. J Pharmacol Exp Ther. 1971 Sep; 178(3):417-24.
     View PubMed
193. Brimijoin S, Trendelenburg U. Reserpine-induced release of norepinephrine from isolated spontaneously beating guinea-pig atria. J Pharmacol Exp Ther. 1971 Jan; 176(1):149-59.
     View PubMed
194. Brimijoin S, Pluchino S, Trendelenburg U. On the mechanism of supersensitivity to norepinephrine in the denervated cat spleen. J Pharmacol Exp Ther. 1970 Nov; 175(2):503-13.
     View PubMed
195. Molinoff PB, Brimijoin S, Weinshilboum R, Axelrod J. Neurally mediated increase in dopamine-beta-hydroxylase activity. Proc Natl Acad Sci U S A. 1970 Jun; 66(2):453-8.
     View PubMed